Ann: CelGro Nerve Regeneration Results in Quadriplegic Patients, page-254

Whitepointer, I am long PAR as well and cannot believe OCC is not in similar territory (mkt cap). It is far further along in the product placement cycle. Either PAR is over-priced or OCC under-priced. I hope the latter. CelGro dental revenues will only continue to grow and soon tendon and nerve repair will add to the revenues.

ATI has been available for years in Australia and its a travesty that it is not more widely recognised (and whilst I appreciate the costs involved in medical marketing I feel the company could have done far better here - it is making renewed efforts). Literally the J&J trials are to confirm for themselves the efficacy of the procedure beyond doubt. Its been well proven in past studies. If they announce some sort of partnership the stock price now will seem absurdly cheap.